Alzheimer's Drug Discovery Foundation logo
The Treat FTD Fund

Treat FTD Fund

Funds early-stage clinical studies for frontotemporal dementia, including prevention trials for high-risk participants.

Opens 2027Alzheimer's Drug Discovery FoundationGlobalDeep-tech · core fit

Eligibility · Global — open worldwide

⚠ This may reflect a past cycle — verify the current call on the funder's site.

The Treat FTD Fund is a joint clinical-trials funding program operated by the Alzheimer's Drug Discovery Foundation (ADDF) and the Association for Frontotemporal Degeneration (AFTD), addressing the critical shortage of interventional studies for frontotemporal degeneration disorders — a rare disease cluster affecting approximately 50,000 to 60,000 Americans with no approved disease-modifying treat

Phase 0, 1, or 2 clinical trials for frontotemporal degeneration disorders. Prevention trials in presymptomatic at-risk individuals also eligible. IND-enabling work must be completed or near-complete.

CycleiHow often this grant runs — e.g. annually, on a rolling basis, or a one-off call.Annual
Next deadlineiThe next date applications are due. Rolling means you can apply any time.
Decision timeiTypical time from the deadline to the funder's decision.
Project durationiHow long the funded work is expected to run.12–36 months
Award typeiThe form of funding — grant, equity, loan, tax credit, etc.Grant
Match fundingiThe share of project costs you must cover yourself. 0% = fully funded.0%
Funding pooliThe total budget available across all awards in this round.

Sign up free to see the funding breakdown

Sign up free to see the industries in scope

Sign up free to see the full eligibility

Sign up free to see how to apply

Sign up free to see what you submit

Sign up free to see the timeline

Last verified: 30 Jun 2026Source: www.alzdiscovery.org